Objectives. Our purpose was to determine the incidence of surgical site infection (SSI) in cancer patients receiving an intrathecal drug delivery system (IDDS) and compare that rate with the incidence of SSI in the general population receiving an IDDS or spinal cord stimulator. We attempted to describe risk factors for SSIs in cancer patients treated with IDDS in terms of exposure to cancer treatments.
Introduction
Pain is a nearly universal experience among patients with cancer, and it is the most common symptom during their illness [1, 2] . Most patients with cancer-related pain can be treated with systemic analgesics according to the World Health Organization (WHO) ladder [3] . In cancer patients with intractable pain, an intrathecal drug delivery system (IDDS) is implanted. Benefits of an IDDS include the ability to provide excellent pain relief with a much lower dosage and with fewer systemic side effects compared with oral, intramuscular, intravenous, or epidural administration [4, 5] .
Complications of IDDS include device malfunction, pharmacologic reaction, and procedurally related complications, including infection and pump malfunction [6] . Infections, in particular, can be treatment-limiting events with clinically significant morbidity, especially with an intrathecal infection. Surgical site infection (SSI) is an infection that occurs within one year after implantation of the device, if the device is not manipulated and if the infection appears to be related to the operation [7] . The US Centers for Disease Control and Prevention (CDC) classification system for SSI includes three subtypes of infections: superficial incisional, deep incisional, and organ/space. Collectively, deep incisional and organ/space infections are known as invasive SSIs and are serious infections that typically require hospitalization, intravenous antibiotic therapy, and, in most cases, device explantation [8] .
SSIs are relatively rare: The reported incidence of infectious complications after IDDS placement ranges from 2.8% to 6.4% [9] [10] [11] [12] . Certain patient risk factors for the development of SSI have been identified, such as advanced age, tobacco use, altered immunity, poorly controlled diabetes mellitus, obesity, and extended surgical time [11, 13] . Guidelines have been provided by the CDC and other groups specializing in neuromodulation for infection risk mitigation for implant systems [8, [13] [14] [15] .
Cancer patients in particular present a challenge to the interventionalist because the overall deconditioning of these patients and their cancer treatments may predispose them to delayed wound healing and SSI, and the risk of SSI is elevated in surgical cancer patients (3%-15%) compared with noncancer patients (3%) [16] . Furthermore, perioperative chemotherapy, immunomodulating agents, and radiotherapy are known risk factors for development of SSIs in surgical cancer patient populations [17, 18] . Many cancer patients also receive corticosteroids as part of their treatment regimen to treat nausea, to improve mood, and to decrease pain. However, corticosteroids compromise immunity by attenuating the action of leukocytes and inflammatory mediators [19] . Long-term use of corticosteroids is associated with an increased rate of postoperative wound infections [17, [20] [21] [22] [23] . The effect of concomitant cancer therapy and the timing of IDDS placement on infection rates in this population are unclear.
The purpose of our study was to determine the incidence of SSI in cancer patients receiving an IDDS and to compare that incidence with the incidence for patients in the general population with implanted IDDSs and spinal cord stimulators. We hypothesized that cancer patients have an increased rate of infectious complications. We hoped that the results of this study would help further identify patients at risk for SSIs after IDDS implantation.
Methods

Inclusion Criteria and Confidentiality
This study was approved by the Mayo Clinic Institutional Review Board. Patients were included if they had received an IDDS for treatment of malignant pain from January 1, 2006, through December 31, 2013, at Mayo Clinic in Rochester, Minnesota. Patients with an IDDS were identified from the electronic surgery scheduling list and departmental billing data. Patient confidentiality was maintained by replacing names and medical record numbers with unique study numbers in the analytical file. Patients were excluded if they did not have a cancer diagnosis or had an IDDS implanted for treatment of nonmalignant pain.
Data Collection
A thorough retrospective chart review was carried out for each patient who met the inclusion criteria. Abstracted demographic data included age, sex, cause of pain, and cancer diagnosis and stage. Treatment with chemotherapy, immunotherapy, or radiotherapy within 90 days before implantation was abstracted from the patients' medical records. Corticosteroid use at implantation was recorded and was considered a positive result if the patient had received dexamethasone for seven or more days within three months before implantation. Postoperative infection surveillance was set at the standard one year after device implantation [7] . Recorded postoperative data included the type of SSI (according to the CDC definition), length of time between implantation and infection, microbiology, antibiotic therapy and duration, surgical exploration, revision or other procedure involving the IDDS, and overall outcome. Data were summarized as means for continuous variables and as estimated proportions for categorical variables.
Results
A total of 64 patients received an IDDS for the treatment of cancer-related pain in the 2006-2013 period. All 64 patients had a preoperative cancer diagnosis. Thirty-five patients (54.7%) were female, and 29 (45.3%) were male. The mean age was 60 years. Within a year after intrathecal pump implantation, 51 patients (80%) had died. The mean surgical time was 116 minutes for patients who did not have an SSI (n ¼ 60) and 114 minutes for those who did have an SSI (n ¼ 4).
Among the four patients who had an SSI (overall infection rate ¼ 6.2%), three (75%) had SSIs that were pocket site infections, and the fourth had a meningitis infection ( Table 1 ). The infections developed between 16 and 88 days after implantation. Three of the four patients with SSIs received corticosteroids at IDDS implantation. Three of the four patients received chemotherapy treatment within 90 days before implantation; the fourth received immunomodulation therapy. Two of the four patients underwent radiotherapy to sites of interest (back, abdomen, pelvis, flank, and sacrum) within 90 days before implantation.
Patient 1 had a meningococcal infection at 43 days after implantation. Cultures from the pump, catheter, and cerebrospinal fluid grew Staphylococcus aureus. The patient underwent explantation promptly (within 24 hours of suspicion for infection) and received intravenous antibiotics for 14 days after explantation. Afterward, therapy was transitioned to oral morphine, oral hydromorphone, and a fentanyl patch for analgesia. He died nine months after pump explantation.
Patient 2 had erythema and drainage at the pump pocket site 16 days after implantation. The patient was discharged home to a remote location. He was offered
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explantation, but his condition was deemed too unstable for an operation. The patient received a course of intravenous antibiotics, and he died two weeks later.
Patient 3 had an infected seroma at the pump pocket site 88 days after a second revision surgery. She underwent explantation. The pocket site culture grew coagulase-negative Staphylococcus. The patient was treated with intravenous vancomycin for two weeks after explantation. Therapy was transitioned to oral methadone for analgesia, and the patient is still undergoing immunotherapy.
Patient 4 had an infected seroma at the pump pocket site 22 days after implantation. He underwent explantation. The catheter had migrated into the paraspinous tissue at explantation. Coagulase-negative Staphylococcus was cultured from an abscess beneath the abdominal incision. After the patient received a course of intravenous antibiotics, therapy was transitioned to oral oxycodone and eventually methadone for pain control. The patient died eight months after explantation.
Six of the 64 patients were lost to follow-up at one year after implantation. All six patients were in stable condition at discharge, with no evidence of infection. Fiftyone patients (80%) died within a year after intrathecal pump implantation; their mean survival was 179 days. Seven of the 64 patients are still alive.
Discussion
With the expansion of its analgesic ladder to a fourth step in 1994, the WHO included interventional pain therapies (eg, spinal analgesia, nerve stimulation, and neurolytic blocks) for helping cancer patients who have refractory pain [24, 25] . Specifically, cancer patients treated with intrathecal morphine instead of systemic opioids survived longer with fewer adverse effects and less pain [4] . However, infections from implantable intrathecal devices can be particularly devastating to this specific patient population.
In our study, SSI occurred at a rate of 6.2%. This is on the higher end of the range of averages for all nationally reported SSIs in all patients receiving an IDDS (2.8-6.4%) [9] [10] [11] [12] . An SSI rate of 6.2% is also higher than the overall infection rate of 3.6% for the spinal cord stimulator and IDDS implant practice at our institution [26] .
Our institution adheres to an implantation protocol that is identical to that at other large institutions and follows published guidelines [7, 8, 13] . The protocol includes a chlorhexidine shower the night before and the morning of surgery, weight-based and properly timed preoperative antibiotics, chlorhexidine skin preparation followed by use of a sterile drape and an iodine-impregnated incisional drape, irrigation of wounds before closure, and watertight, layered surgical closure. The procedure is done in a sterile fashion. The choice of material for skin closure is at the discretion of the implanting physician; materials used in our study were staples and absorbable and nonabsorbable sutures. After the procedure, the wounds are kept covered for 48 hours with an aseptically placed occlusive dressing, and if staples or nonabsorbable skin sutures are used, they are removed in 10 to 14 days. The recommended preoperative antibiotics are 1) a cephalosporin, for patients without a penicillin allergy; 2) vancomycin, for patients with known methicillin-resistant Staphylococcus aureus colonization; or 3) either clindamycin or vancomycin for patients with a penicillin or cephalosporin allergy. Postoperative antibiotics are not routinely used, but they may be considered on a caseby-case basis according to the implanters' preferences and the patients' specific risks.
The four patients with an SSI had received at least one form of cancer therapy (chemotherapy, immunotherapy, radiotherapy, or corticosteroids). These treatments are known to increase the risk of SSI. Chemotherapy Table 1 Cancer patients with surgical site infections after implantation of an intrathecal drug delivery system is a risk factor for wound infection complications in patients postoperatively, even in the absence of leukopenia (leukocyte count < 4.0 Â 10 9 /L) [17, 27] . (At our institution, an IDDS is not implanted in a patient who is neutropenic.) Patients were classified as having exposure to the risk factor if they had received a course of chemotherapy, immunotherapy, or radiotherapy within 90 days before implantation. Data are limited on the extent of immunosuppression after exposure to individual cancer treatments. The 90-day period was used in this study according to CDC guidelines for patients who are severely immunocompromised after chemotherapy treatment [28] . However, the timing of the immunocompromising effect of each cancer treatment around IDDS implantation is variable, and its significance in the infection rate is unknown. Perhaps the duration of cancer treatment or the exposure closer to the date of implantation have an unidentified effect.
Similarly, corticosteroid use is a known risk factor for postoperative wound infections in patients who have cancer and in patients who do not [21, 22] . In our study, at implantation three of the four patients with an SSI were receiving corticosteroids (oral daily dexamethasone, with a minimum of a seven-day course in the past 90 days). The overall duration of treatment and immediate exposure were not evaluated. It is unknown whether this effect is dose dependent; however, this has been suggested for other surgical populations [22, 23] .
The CDC classification system for SSI includes three subtypes: superficial incisional, deep incisional, and organ/space infections. Superficial incisional SSIs often do not require rehospitalization and are instead frequently diagnosed in outpatients during postimplant surveillance. Collectively, deep incisional and organ/space infections are known as invasive SSIs and are serious infections that typically require hospitalization, intravenous antibiotic therapy, and, in most cases, device explantation [8] . In a study by Engle et al. [11] , the authors reported that all device infections occurred at the pulse generator or the pump pocket site. Follett et al. [8] also reported a higher risk of infection at the pocket site for implantable devices, with 72% of infections for implantable pump therapies occurring at the pocket site. Results of the present study were consistent with those in previous reports, with 75% of the SSIs identified as pump pocket site infections, or deep infections, and just one organ/space infection. Some studies suggest that chemotherapy, use of corticosteroids, and the radiotherapy regimen may have differential effects on the type of SSI. The disease process in deep and organ/space SSIs differs from that in superficial SSIs. The use of chemotherapy in combination with corticosteroids has been associated with only organ/space infections [17] . In other studies involving preoperative radiotherapy, this particular risk factor was associated with both organ/space and deep infections but not superficial infections [18] .
The patient in our study with the most serious organ/ space infection (meningitis) received all four types of cancer treatment within the 90-day period. However, several patients in our study also underwent the four types of cancer treatment and did not have infections; therefore, conclusions from this observation are limited. Also, this patient did not have other identifiable risk factors, such as concomitant infection, diabetes mellitus, obesity, neutropenia (leukocyte count < 6.1 Â 10 9 /L), or extended operative time (94 minutes, which is less than the mean of 116 minutes in our study). The implantation was carried out according to the protocol, and the patient was given preoperative and postoperative antibiotics.
Several findings in our study emphasized the deleterious effect of SSIs on patients' quality of life. Three of our patients who had an SSI underwent explantation of the IDDS. After explantation, at least one of the patients had multiple readmissions for intractable pain. The patient who did not undergo explantation died two weeks after the SSI diagnosis. This patient had aggressive metastatic periurethral cancer and was discharged to his remote home after implantation. Subsequently, purulent drainage developed, with erythema and air-gas levels at the pump pocket site on computed tomography. Antibiotics were administered intravenously by his local physician, and explantation was offered by the original interventionalist. However, because of the severity of this patient's illness, he did not undergo explantation.
Our study had several limitations. The most notable was its retrospective nature. Because of the limited number of patients with SSI, the power was insufficient to draw conclusions. To increase the power, multicenter collaboration would be imperative. With the relatively small number of patients, we did not control for all confounding variables with a multivariate regression model. Six patients were lost to follow-up at discharge to their home institution. Those patients were in stable condition at discharge, but a small number of unaccounted SSIs could significantly affect the data.
We have shown that cancer patients may be at increased risk for SSI compared with patients without cancer according to our institution's database. This study is merely the first step in identifying the infection rate among cancer patients with an IDDS and describing the risk that cancer treatment may pose. Ultimately, the determination of these particular risk factors for SSI after IDDS implantation will allow providers to identify patients with a higher risk for infection. This may lead to additional prophylaxis, reevaluation of the necessity of the therapy, and implementation of the correct timing of the IDDS in relation to these risk factors. Because of the severity of these patients' illnesses and the time sensitivity of these cancer treatments, it will likely be more appropriate for the interventionalist to enhance preoperative prophylaxis measures rather than reschedule cancer treatment for the individual cancer patient. As the field of implantable pain delivery systems progresses, these factors should be identified so that modifications in practice can be made to improve complication rates, reduce the cost burden to society, and improve the quality of life of these patients.
Conclusion
Cancer patients have several risk factors that may predispose them to SSIs at a higher rate than the average population, such as chemotherapy, use of corticosteroids, radiotherapy, and immunomodulators. Large multicenter studies are needed to clearly identify patients at risk for SSI to reduce the incidence of infectious complications after IDDS placement in patients with cancer.
